P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX). (23rd June 2022) - Gupta, V.; Yacoub, A.; Verstovsek, S.; Mesa, R. A.; Harrison, C. N.; Barosi, G.; Kiladjian, J.-J.; Deeg, H. J.; Fazal, S.; Foltz, L.; Mattison, R. J.; Miller, C. B.; et al.